Routes of
administration Oral | ||
 | ||
Legal status US: Investigational New Drug | ||
EPI-506, developed by ESSA Pharmaceuticals, is an experimental non-steroidal antiandrogen in clinical trials for prostate cancer. It is the successor of EPI-001 and targets the N-terminal domain of the androgen receptor (AR). This mechanism of action is believed to allow the drug to block signaling from the AR and its splice variants. EPI-506 is a prodrug of EPI-002, one of the four stereoisomers of EPI-001.
As of January 2017, ESSA is recruiting patients for a phase I/II clinical trial for castration-resistant prostate cancer.
References
EPI-506 Wikipedia(Text) CC BY-SA